Doris M.
Doris M. Benbrook, Oklahoma City, OK US
Patent application number | Description | Published |
---|---|---|
20100105757 | TREATMENT AND INHIBITION OF DISEASE CONDITIONS USING FLEXIBLE HETEROAROTINOIDS - The present invention contemplates methods of treating, reducing, inhibiting or preventing several diseases by the administration of flexible heteroarotinoids. Among the diseases or conditions which can benefit from treatment with flexible heteroarotinoids as described herein are, (1) cancers and other diseases that involve abnormal differentiation, (2) diabetes, (3) hemophelia, (4) liver disease, (5) diseases involving human aldehyde dehydrogenase 2, (6) polycystic kidney disease, (7) lysosomal storage diseases, (8) high cholesterol, (9) obesity, (10) high triglycerides, (11) glycoprotein metabolism diseases, and (12) diseases involving abnormal angiogenesis. | 04-29-2010 |
20130184323 | TREATMENT OF ENDOPLASMIC RETICULUM STRESS-RELATED DISEASES AND CONDITIONS - A method of treating a disease or condition associated with at least one of a cellular accumulation of unfolded and/or misfolded proteins, an abnormal unfolded protein response (UPR), an endoplasmic reticulum (ER) stress, and an abnormal autophagy response, is disclosed. The method may include administering one or more flexible heteroarotinoid compounds which target, bind to, disrupt, and/ or modulate the activity of one or more of heat shock proteins | 07-18-2013 |
Doris M. Haverstick, Charlottesville, VA US
Patent application number | Description | Published |
---|---|---|
20100222406 | T Type Calcium Channel Blockers and the Treatment of Diseases - The present invention provides a method for treating a disease or condition in a mammal associated with influx of extracellular calcium via T type calcium channels, which comprises administering to the mammal a therapeutically effective amount of a T type calcium channel inhibitor, a prodrug thereof, or a pharmaceutically acceptable salt of said inhibitor or prodrug, wherein the T type calcium channel inhibitor has a structure represented by Formula (I): Formula (I), wherein R | 09-02-2010 |
20120264804 | T TYPE CALCIUM CHANNEL BLOCKERS AND THE TREATMENT OF DISEASES - The present invention provides a method for treating a disease or condition in a mammal associated with influx of extracellular calcium via T type calcium channels, which comprises administering to the mammal a therapeutically effective amount of a T type calcium channel inhibitor, a prodrug thereof, or a pharmaceutically acceptable salt of said inhibitor or prodrug, wherein the T type calcium channel inhibitor blocks a splice variant of an α1H isoform of T type calcium channels. | 10-18-2012 |
20140087964 | COMPOSITIONS AND METHODS FOR DETECTING ABERRANT REGULATION, EXPRESSION, AND LEVELS OF HGH - Detection of human growth hormone use is very challenging due to the short half-life of circulating human growth hormone and the fact that the recombinant human growth hormone used is identical in protein sequence as the native, naturally produced growth hormone. The chief objective of this invention is to discover a marker(s) that will identify use of recombinant human growth hormone use. In the case of this invention, we have discovered specific circulating micro RNA (miRNA) that can be detected and quantified in plasma of individuals taking recombinant human growth hormone. | 03-27-2014 |
Doris M. Haverstick, Chalottesville, VA US
Patent application number | Description | Published |
---|---|---|
20090234019 | T Type Calcium Channel Inhibitors - The present invention provides novel T type calcium channel inhibitors of formula (I), the use thereof in the treatment of a disease or condition in a mammal associated with influx of extracellular calcium via T type calcium channels, | 09-17-2009 |